Table 1.
General data about the test subjects.
| Variable | Group | Data | Statistics; p Value |
|---|---|---|---|
| Total number | 155 | ||
| Sex (n (%)) | Male | 101 (65.2%) | |
| Female | 54 (34.2%) | ||
| Age (M ± SD) | 41.7 ± 11.9 years | ||
|
Age by sex
(M ± SD) |
Male | 39.5 ± 11.4 | t = −3.190, p = 0.002 |
| Female | 45.7 ± 11.9 | ||
|
PRL level
(M ± SD) |
27.41 ± 19.70 ng/mL | ||
|
PRL level by sex
(M ± SD) |
Male | 19.33 ± 11.01 | t = −6.914, p < 0.001 |
| Female | 42.21 ± 23.28 | ||
|
Number of patients by PRL group
(n (%)) |
Normal PRL | 85 (54.8%) | |
| Asymptomatic HPRL | 37 (23.9%) | ||
| Symptomatic HPRL | 33 (21.3%) | ||
| PRL level by PRL group (M ± SD) | Normal PRL | 14.08 ± 6.00 ng/mL | F = 142.559; p < 0.001 |
| Asymptomatic HPRL | 38.18 ± 11.78 ng/mL | ||
| Symptomatic HPRL | 53.01 ± 19.97 ng/mL | ||
| Age by PRL group (M ± SD) | Normal PRL | 40.3 ± 11.4 years | F = 1.367; p = 0.258 |
| Asymptomatic HPRL | 42.6 ± 12.8 years | ||
| Symptomatic HPRL | 44.1 ± 12.1 years | ||
|
Number of patients by drug form
(n (%)) |
Oral risperidone | 51 (32.9%) | |
| LAI-R | 29 (18.7%) | ||
| LAI-Pm | 33 (21.3%) | ||
| LAI-Pq | 42 (27.1%) | ||
|
Age by drug form
(M ± SD) |
Oral risperidone | 41.16 ± 1.8 years | F = 0.099; p = 0.961 |
| LAI-R | 42.25 ± 2.8 years | ||
| LAI-Pm | 42.18 ± 2.0 years | ||
| LAI-Pq | 41.38 ± 1.8 years | ||
|
Duration of therapy
(n (%)) |
Under 6 months | 42 (27.1%) | |
| 6–12 months | 25 (16.1%) | ||
| Over 12 months | 88 (56.8%) | ||
|
Age by duration of therapy
(M ± SD) |
Under 6 months | 38.26 ± 12.8years | F = 6.210; p = 0.003 |
| 6–12 months | 37.33 ± 11.4years | ||
| Over 12 months | 44.50 ± 10.9 years |
M—mean; SD—standard deviation; PRL—prolactine; HPRL—hyperprolactinemia; LAI-R—long-acting injections of risperidone; LAI-Pm—long-acting injections of paliperidone monthly; LAI-Pq—long-acting injections of paliperidone quarterly.